Clinical evaluation of a specific benzodiazepine antagonist (RO 15-1788). Studies in elderly patients after regional anaesthesia under benzodiazepine sedation.
The efficacy, usefulness and side effects of RO 15-1788 (RO), a specific benzodiazepine (BZD) antagonist, have been evaluated. Sixty-two patients (ASA I-III, mean age 72 +/- 9 yr) scheduled for urological surgery under regional anaesthesia and BZD sedation received placebo or RO in a randomized, double-blind fashion at the end of the procedure, following sedation with midazolam. When compared with placebo, RO improved alertness and collaboration for 15 min, and suppressed anterograde amnesia for 60 min. No major side effect was noted, although five patients became anxious after administration of RO. Two cases of a paradoxical reaction to midazolam were treated successfully by RO.
D000368:Aged; D000647:Amnesia / Q000139:chemically induced; D000762:Anesthesia Recovery Period; D000765:Anesthesia, Conduction; D001569:Benzodiazepines / Q000037:antagonists & inhibitors*; D004341:Drug Evaluation; D005260:Female; D005442:Flumazenil / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000037:antagonists & inhibitors; D008297:Male; D008874:Midazolam / Q000037:antagonists & inhibitors*; D008875:Middle Aged; D014797:Vital Capacity / Q000187:drug effects
D006993:Hypnotics and Sedatives; D001569:Benzodiazepines; D005442:Flumazenil; D008874:Midazolam